Your browser doesn't support javascript.
loading
A strategy to reconstitute immunity without GVHD via adoptive allogeneic Tscm therapy.
Guan, Liping; Sun, Yunqin; Si, Yanli; Yan, Qingya; Han, Ziyu; Liu, Youxun; Han, Tao.
Afiliação
  • Guan L; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
  • Sun Y; Clinical Department, Sanquan College of Xinxiang Medical University, Xinxiang, China.
  • Si Y; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
  • Yan Q; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
  • Han Z; Xinxiang Key laboratory for Molecular Oncology, Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang, China.
  • Liu Y; Xinxiang Key laboratory for Molecular Oncology, Institutes of Health Central Plains, Xinxiang Medical University, Xinxiang, China.
  • Han T; School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
Front Immunol ; 15: 1367609, 2024.
Article em En | MEDLINE | ID: mdl-39035005
ABSTRACT

Introduction:

Adoption of allogeneic T cells directly supplements the number of T cells and rapidly induces T-cell immunity, which has good efficacy for treating some tumors and immunodeficiency diseases. However, poor adoptive T-cell engraftment and graft-versus-host disease (GVHD) limit the application of these methods. Alloreactive T-cell clones were eliminated from the donor T-cell repertoire, and the remaining T-cell clones were prepared as Tscm for T-cell adoptive treatment to reconstruct recipient T-cell immunity without GVHD.

Methods:

The subjects in this study included three different strains of mice. Lymphocytes from mice (C57BL/6) were used as the donor T-cell repertoire, from which the Tscm allo-reactive T cell clone was depleted (ATD-Tscm). This was confirmed by showing that the Tscm was not responsive to the alloantigen of the recipient (BALB/c). To prepare ATD-Tscm cells, we used recipient lymphocytes as a simulator, and coculture of mouse and recipient lymphocytes was carried out for 7 days. Sorting of non-proliferative cells ensured that the prepared Tscm cells were nonresponsive. The sorted lymphocytes underwent further expansion by treatment with TWS119 and cytokines for an additional 10 days, after which the number of ATD-Tscm cells increased. The prepared Tscm cells were transferred into recipient mice to observe immune reconstitution and GVHD incidence.

Results:

Our protocol began with the use of 1×107 donor lymphocytes and resulted in 1 ×107 ATD-Tscm cells after 17 days of preparation. The prepared ATD-Tscm cells exhibited a nonresponse upon restimulation of the recipient lymphocytes. Importantly, the prepared ATD-Tscm cells were able to bind long and reconstitute other T-cell subsets in vivo, effectively recognizing and answering the "foreign" antigen without causing GVHD after they were transferred into the recipients.

Discussion:

Our strategy was succeeded to prepare ATD-Tscm cells from the donor T-cell repertoire. The prepared ATD-Tscm cells were able to reconstitute the immune system and prevent GVHD after transferred to the recipients. This study provides a good reference for generating ATD-Tscm for T-cell adoptive immunotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro / Camundongos Endogâmicos C57BL Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro / Camundongos Endogâmicos C57BL Idioma: En Ano de publicação: 2024 Tipo de documento: Article